Pancreatic Cancer Research

ResearcherZhejiang Provincial People's HospitalActive in the last 2 years

Ying Xin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7591-9423; OpenAlex author ID A5038696088. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. [Retracted] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2025.13475↗
  2. [Corrigendum] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2022.12738↗
  3. miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2018.8941↗
  4. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. Co-author DOI 10.1007/s00280-014-2397-9↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yunpeng Peng · 3 shared papers, 2018–2025 · strength 0.49
  2. Jishu Wei · 3 shared papers, 2018–2025 · strength 0.49
  3. Xinchun Liu · 3 shared papers, 2018–2025 · strength 0.49
  4. Bin Chen · 2 shared papers, 2022–2025 · strength 0.41
  5. Yi Miao · 2 shared papers, 2022–2025 · strength 0.41
  6. Jingjing Zhang · 1 shared paper, 2025 · strength 0.26
  7. Jingjing Zhang · 1 shared paper, 2022 · strength 0.16
  8. Bin Chen · 1 shared paper, 2018 · strength 0.08
  9. Yi Miao · 1 shared paper, 2018 · strength 0.08
  10. Defei Hong · 1 shared paper, 2014 · strength 0.06
  11. Bin Chen · 1 shared paper, 2014 · strength 0.06
  12. Long Cheng · 1 shared paper, 2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.